Aquestive Therapeutics logo
Aquestive Therapeutics AQST
$ 4.6 -2.85%

Quarterly report 2024-Q3
added 11-04-2024

report update icon

Aquestive Therapeutics Balance Sheet 2011-2024 | AQST

Annual Balance Sheet Aquestive Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

21.5 M 6.43 M -25.2 M 5.1 M 11 M -13.4 M 28.1 M 29.4 M - - - - -

Long Term Debt

45 M 33.4 M 1.95 M 34.3 M 60.3 M 42.6 M 45.5 M 38.6 M - - - - -

Long Term Debt Current

390 K 255 K 899 K 728 K - - - - - - - - -

Total Non Current Liabilities

- - - 90.3 M 66 M 43.8 M 54.3 M 46.2 M - - - - -

Total Current Liabilities

18.3 M 39.5 M 22 M 21.1 M 18.6 M 33 M - - - - - - -

Total Liabilities

164 M 176 M 144 M 111 M 84.6 M 76.8 M 69.6 M 57 M - - - - -

Deferred Revenue

1.55 M 1.51 M 765 K 693 K 806 K 721 K 1.35 M 802 K - - - - -

Retained Earnings

-319 M -311 M -257 M -186 M -130 M -61.4 M -120 M -109 M - - - - -

Total Assets

57.4 M 57.1 M 62 M 62.9 M 78.5 M 86.9 M 43.1 M 39.4 M - - - - -

Cash and Cash Equivalents

23.9 M 27.3 M 28 M 31.8 M 49.3 M 60.6 M - - - - - - -

Book Value

-106 M -119 M -82.1 M -48.5 M -6.12 M 10.1 M -26.5 M -17.6 M - - - - -

Total Shareholders Equity

-106 M -119 M -82.1 M -48.5 M -6.12 M 10.1 M -68.6 M - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Aquestive Therapeutics

2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

45 M 45 M 45 M 14.8 M 39 M 39 M 42.4 M 5.08 M 51.5 M - 51.5 M 1.95 M 51.5 M 51.5 M 51.5 M 51.5 M 70 M 70 M 70 M 70 M 70 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

155 M 153 M 166 M 164 M 162 M 164 M 171 M 176 M 160 M - 150 M 144 M 126 M 121 M 114 M 111 M 111 M 111 M 111 M 84.6 M 84.6 M 84.6 M 84.6 M 76.8 M 76.8 M 76.8 M 76.8 M 69.6 M 69.6 M 69.6 M - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

1.05 M 1.05 M 1.55 M 1.55 M 2.64 M 3.99 M 4.76 M 1.51 M 774 K - 1.6 M 765 K 767 K 642 K 437 K 693 K 693 K 693 K 693 K 806 K 806 K 806 K 806 K 721 K 721 K 721 K 721 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-346 M -335 M -332 M -319 M -311 M -309 M -303 M -311 M -299 M - -270 M -257 M -228 M -213 M -201 M -186 M -186 M -186 M -186 M -130 M -130 M -130 M -130 M -61.4 M -61.4 M -61.4 M -61.4 M -120 M -120 M -120 M - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

110 M 118 M 130 M 57.4 M 59.4 M 57 M 61.3 M 57.1 M 51.8 M - 56.5 M 62 M 65.3 M 66.9 M 61.9 M 62.9 M 62.9 M 62.9 M 62.9 M 78.5 M 78.5 M 78.5 M 78.5 M 86.9 M 86.9 M 86.9 M 86.9 M 43.1 M 43.1 M 43.1 M - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

77.9 M 89.9 M 95.2 M 23.9 M 24.9 M 22.4 M 26.9 M 27.3 M 18.6 M 17.7 M 14.7 M 28 M 31.2 M 34.2 M 27.5 M 31.8 M 17.1 M 31.8 M 31.8 M 49.3 M 49.3 M 49.3 M 49.3 M 60.6 M 60.6 M 60.6 M 60.6 M 17.4 M 17.4 M 17.4 M - 9.21 M - - - - - - - - - - - - - - - - - - - - - - -

Book Value

-45.4 M -35.5 M -36.3 M -106 M -103 M -107 M -109 M -119 M -108 M - -93.1 M -82.1 M -60.3 M -53.8 M -51.8 M -48.5 M -48.5 M -48.5 M -48.5 M -6.12 M -6.12 M -6.12 M -6.12 M 10.1 M 10.1 M 10.1 M 10.1 M -26.5 M -26.5 M -26.5 M - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

-45.4 M -35.5 M -36.3 M -106 M -103 M -107 M -109 M -119 M -108 M -96.4 M -93.1 M -82.1 M -60.3 M -53.8 M -51.8 M -48.5 M -48.5 M -48.5 M -48.5 M -6.12 M -6.12 M -6.12 M -6.12 M 10.1 M 10.1 M 10.1 M 10.1 M -26.5 M -68.6 M -68.6 M - -57.2 M - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency